Jadenu (Deferasirox) Patent Expiration, LOE Window & CMS Spending

Jadenu (Deferasirox) by Novartis: FDA Orange Book core substance LOE 2034-11-21, 11 AB generics, $12.9M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN206910 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-11-21
Last Listed Patent or Exclusivity Date2034-11-21
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$12.9M
2024 Medicare Part D Spend$7.8M
2024 Medicaid Spend$5.1M
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 24.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.